Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

TP53 Y220C Mutation 1Prostate Cancer Patients 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Healthy Adult Participants 1Gastrointestinal Stromal Tumors 1Diabetes Mellitus, Type 2 1Advanced Solid Tumor 1Advanced Malignancies 1

Interventions

Gemcitabine 683130-nm albumin-bound paclitaxel 198Fluorouracil 188Oxaliplatin 175Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 131Irinotecan 112Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 72Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 50Cyclophosphamide 49folfirinox 45Specimen Handling 42Docetaxel 42Cetuximab 40irinotecan sucrosofate 38Biopsy 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × repaglinide × Clear all
NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡